BR112012013164A2 - pharmaceutical compositions for stem cell stimulation - Google Patents

pharmaceutical compositions for stem cell stimulation

Info

Publication number
BR112012013164A2
BR112012013164A2 BR112012013164A BR112012013164A BR112012013164A2 BR 112012013164 A2 BR112012013164 A2 BR 112012013164A2 BR 112012013164 A BR112012013164 A BR 112012013164A BR 112012013164 A BR112012013164 A BR 112012013164A BR 112012013164 A2 BR112012013164 A2 BR 112012013164A2
Authority
BR
Brazil
Prior art keywords
stem cell
cell stimulation
pharmaceutical compositions
stimulation
human
Prior art date
Application number
BR112012013164A
Other languages
Portuguese (pt)
Inventor
Christian Homsy
Jean-Pierre Latere Dwan Lsa
Roland Gordon-Beresford
Vinciane Gaussin
Original Assignee
Cardio 3 Biosciences S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardio 3 Biosciences S A filed Critical Cardio 3 Biosciences S A
Publication of BR112012013164A2 publication Critical patent/BR112012013164A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições farmacêuticas para o estímulo de células-tronco. a presente invenção refere-se à composição farmacêutica (b) para uso humano ou veterinário, para estímulo de células-tronco, compreendendo pelo menos dois agentes estimulante de células-tronco e pelo menos um excipiente farmaceuticamente aceitável.pharmaceutical compositions for stem cell stimulation. The present invention relates to pharmaceutical composition (b) for human or veterinary use for stem cell stimulation comprising at least two stem cell stimulating agents and at least one pharmaceutically acceptable excipient.

BR112012013164A 2009-12-02 2010-12-02 pharmaceutical compositions for stem cell stimulation BR112012013164A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2009066251 2009-12-02
PCT/EP2010/068700 WO2011067317A1 (en) 2009-12-02 2010-12-02 Pharmaceutical compositions for the stimulation of stem cells.

Publications (1)

Publication Number Publication Date
BR112012013164A2 true BR112012013164A2 (en) 2016-03-01

Family

ID=42316097

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013164A BR112012013164A2 (en) 2009-12-02 2010-12-02 pharmaceutical compositions for stem cell stimulation

Country Status (12)

Country Link
JP (1) JP2013512877A (en)
KR (1) KR20120099751A (en)
CN (1) CN102711798A (en)
AU (1) AU2010326633A1 (en)
BR (1) BR112012013164A2 (en)
CA (1) CA2781493A1 (en)
IL (1) IL219901A0 (en)
MX (1) MX2012005976A (en)
NZ (1) NZ599930A (en)
RU (1) RU2012120834A (en)
TW (1) TW201141510A (en)
WO (1) WO2011067317A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000699A1 (en) * 2014-07-07 2016-01-07 Medipost Co., Ltd. Hair growth promoting capacity of conditioned media of stimulated stem cells and use thereof
CN105079791A (en) * 2015-09-18 2015-11-25 郑榆坤 Composition for stimulating endogenous stem cells in vivo and application of composition
RU2634576C1 (en) * 2016-10-24 2017-10-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Method for tissue regeneration stimulation
CN107050428B (en) * 2017-03-23 2020-05-05 温州医科大学 FGF20 medicament and application thereof in treatment of cerebral trauma
CN107648592B (en) * 2017-11-13 2021-05-14 深圳市喆邦生物工程有限公司 Application of chemokine CCL4 in preparation of medicine for treating bone fracture
RU2686718C1 (en) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Agent stimulating mesenchymal progenitor cell functions in vitro
KR102106710B1 (en) 2018-10-11 2020-05-04 강원대학교산학협력단 hematopoietic differentiation of human pluripotent stem cells in a developmental stage-specific manner
CN111195350A (en) * 2020-01-15 2020-05-26 重庆大学 Application of combination of IGF1 and IGF1Ec24 in preparation of medicines for promoting tissue repair and regeneration
WO2021187895A1 (en) * 2020-03-17 2021-09-23 주식회사 히에라바이오 Composition for preventing or treating ischemic diseases, comprising cardiac stem cells
CN111621525B (en) * 2020-06-18 2021-04-23 中赛干细胞基因工程有限公司 Application of STX1B gene in promoting growth and differentiation of human adipose-derived mesenchymal stem cells
KR20240131080A (en) * 2023-02-23 2024-08-30 서울대학교산학협력단 Medium composition for culture of extraembryonic endoderm stem cells
CN116836920B (en) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 Serum-free culture medium and method for preparing mesenchymal stem cells by using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1786471B1 (en) * 2004-07-30 2015-02-11 Mayo Foundation For Medical Education And Research Treating cardiovascular tissue
AU2006208241B2 (en) * 2005-01-25 2011-08-04 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
US9765298B2 (en) * 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
US8481075B2 (en) * 2007-12-13 2013-07-09 Beijing Shengyiyao Science & Technology Development Co. Ltd. Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines

Also Published As

Publication number Publication date
KR20120099751A (en) 2012-09-11
AU2010326633A1 (en) 2012-05-31
RU2012120834A (en) 2014-01-20
TW201141510A (en) 2011-12-01
NZ599930A (en) 2014-04-30
IL219901A0 (en) 2012-07-31
MX2012005976A (en) 2012-06-25
CA2781493A1 (en) 2011-06-09
CN102711798A (en) 2012-10-03
WO2011067317A1 (en) 2011-06-09
JP2013512877A (en) 2013-04-18

Similar Documents

Publication Publication Date Title
BR112012013164A2 (en) pharmaceutical compositions for stem cell stimulation
CR11731A (en) COMPOSITIONS AND PROCEDURES FOR PREPARATION AND USE
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
CL2012001605A1 (en) Quinoline-2-carboxamide derived compounds, positive allosteric modulators of the muscarine m1 receptor; pharmaceutical composition comprising the compound; and its use in the preparation of drugs for the treatment of diseases such as Alzheimer's, pain or sleep disorders.
AR092177A1 (en) METHODS TO TREAT OR PREVENT ASTHMA BY MANAGING AN IL-4R ANTAGONIST
BR112015011036A2 (en) heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
BR112015003188A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, COMPOUND USE, AND METHOD FOR TREATMENT OF A RORGAMMAT-MEDIATED DISEASE OR CONDITION IN A PATIENT
CL2014000956A1 (en) Compounds derived from (4-phenylimidazol-2-yl) ethylamine, such as sodium channel modulators; pharmaceutical composition that includes them; and its use in the treatment of pain.
CR20110509A (en) PHARMACEUTICAL COMPOSITION
HN2011003011A (en) SUBLINGUAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM
BR112015024411A2 (en) macrocyclic desaza purinones for the treatment of viral infections
GT201200313A (en) 5-FLUORO-1H-REPLACED PIRAZOLOPIRIDINES AND ITS USE
GT200900230A (en) 4-ARIL-1,4-DIHIDRO-1,6-NAFTIRIDINAMIDES REPLACED AND USE
BR112015018087A8 (en) compound, pharmaceutical composition and use
BRPI1006825A2 (en) pro-neurogenic compounds
BR112012016398A2 (en) Substituted imidazopyridinyl-aminopyridine compound, pharmaceutical composition comprising said compound and use thereof for the treatment of a proliferative cell disease
HN2011001593A (en) VIRF-R2 PIRIDYLOXI-INDOLES AND USE OF THE SAME FOR THE TREATMENT OF DISEASES
PA8772101A1 (en) IMIDAZOL-TRIAZOLOPIRIMIDINAS REPLACED
BR112014021531A2 (en) compound, pharmaceutical composition and uses thereof
BR112015007366A2 (en) acylaminopyrimidine derivatives for the treatment of viral infections and other diseases
NI201000044A (en) BUPROPION BROMHYDRATE AND THERAPEUTIC APPLICATIONS
CL2007002018A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED ISOXAZOLINS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND FOR THE TREATMENT OF A DISEASE CAUSED BY AN INCREASE IN THE CELL PROLIFERATION.
CR20120040A (en) DERIVATIVES OF 17-HIDROXI-17-PENTAFLUOROETIL-ESTRA-4,9 (10) -DIEN-11-ARILO, PROCEDURES FOR THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF DISEASES
ECSP109923A (en) BUPROPION BROMHYDRATE AND THERAPEUTIC APPLICATIONS
CL2008001820A1 (en) Aryl-isoxasol-imidazole derived compounds; preparation procedure; pharmaceutical composition containing them; and use in the preparation of useful drugs in the treatment of cognitive disorders and Alzheimer's-related diseases.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]